REGAN RONEY: Open Payments
NPI 1730675612 · LAUREL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,240 in 68 payments from 19 companies in 2025. Trend: 2023 $65 · 2024 $666 · 2025 $1,240
Food & beverage: $1,240
| Company | Payments | Amount |
|---|---|---|
| ACADIA Pharmaceuticals Inc | 8 | $178 |
| Lilly USA, LLC | 11 | $170 |
| ABBVIE INC. | 11 | $152 |
| PFIZER INC. | 10 | $145 |
| Otsuka America Pharmaceutical, Inc. | 4 | $102 |
| ARGENX US, INC. | 3 | $58 |
| Lundbeck LLC | 3 | $58 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
Products named: NUPLAZID, NURTEC ODT, KISUNLA, REXULTI, QULIPTA, VYVGART HYTRULO, VYEPTI, KESIMPTA.
Industry payments across MS — which companies pay providers there.
